Shares of Vericel Co. (NASDAQ:VCEL – Get Free Report) have been given an average rating of “Buy” by the seven research firms that are covering the firm, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $57.71.
VCEL has been the topic of several recent analyst reports. Canaccord Genuity Group assumed coverage on Vericel in a research note on Friday, August 9th. They issued a “buy” rating and a $57.00 price target on the stock. Truist Financial boosted their price objective on Vericel from $56.00 to $57.00 and gave the company a “buy” rating in a research note on Tuesday, July 16th. TD Cowen boosted their price objective on Vericel from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Tuesday, August 27th. BTIG Research dropped their price target on Vericel from $56.00 to $55.00 and set a “buy” rating on the stock in a research note on Monday, July 15th. Finally, Canaccord Genuity Group initiated coverage on Vericel in a research note on Friday, August 9th. They set a “buy” rating and a $57.00 price target on the stock.
Read Our Latest Analysis on VCEL
Insider Buying and Selling
Institutional Investors Weigh In On Vericel
Several institutional investors and hedge funds have recently made changes to their positions in VCEL. UniSuper Management Pty Ltd acquired a new stake in shares of Vericel in the first quarter valued at about $595,000. BNP Paribas Financial Markets boosted its holdings in shares of Vericel by 99.7% in the 1st quarter. BNP Paribas Financial Markets now owns 111,760 shares of the biotechnology company’s stock valued at $5,814,000 after buying an additional 55,796 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its stake in Vericel by 10.9% during the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,021,695 shares of the biotechnology company’s stock worth $53,149,000 after purchasing an additional 100,797 shares during the period. Silvercrest Asset Management Group LLC acquired a new stake in Vericel during the 1st quarter worth $6,538,000. Finally, Geneva Capital Management LLC boosted its holdings in shares of Vericel by 43.6% in the first quarter. Geneva Capital Management LLC now owns 679,165 shares of the biotechnology company’s stock valued at $35,330,000 after acquiring an additional 206,202 shares in the last quarter.
Vericel Price Performance
Shares of Vericel stock opened at $42.87 on Friday. The company has a market capitalization of $2.08 billion, a P/E ratio of -4,287.00 and a beta of 1.67. Vericel has a 1 year low of $32.28 and a 1 year high of $54.10. The business has a 50-day moving average of $45.03 and a two-hundred day moving average of $46.51.
Vericel (NASDAQ:VCEL – Get Free Report) last released its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.10). Vericel had a return on equity of 0.35% and a net margin of 0.37%. The company had revenue of $52.70 million during the quarter, compared to analysts’ expectations of $52.59 million. During the same period last year, the firm posted ($0.11) earnings per share. The business’s revenue was up 14.8% on a year-over-year basis. On average, equities analysts anticipate that Vericel will post 0.12 EPS for the current fiscal year.
About Vericel
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.
Read More
- Five stocks we like better than Vericel
- Do ETFs Pay Dividends? What You Need to Know
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- Using the MarketBeat Dividend Yield Calculator
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- Differences Between Momentum Investing and Long Term Investing
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.